Press Release

<< Back
View printer-friendly version

Spark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a.m. to Discuss SPK-9001 Phase 1/2 Data for the Treatment of Hemophilia B Presented at EHA

Company also will provide an update on preclinical data on SPK-FVIII for the treatment of Hemophilia A

PHILADELPHIA, June 09, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) announced today that it will host a conference call on Monday, June 13, 2016 at 8:30 a.m. ET to discuss updated results of the first cohort from the ongoing Phase 1/2 clinical trial of SPK-9001, the lead investigational compound in the SPK-FIX program in collaboration with Pfizer, Inc., which is being studied for the treatment of hemophilia B.  Spark also will provide an update on preclinical data in its SPK-FVIII program for the treatment of hemophilia A.

Initial results of the ongoing Phase 1/2 clinical trial of SPK-9001 will be presented on Saturday June 11, 2016, at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark. Dr. Katherine High, president and chief scientific officer of Spark, will present at the press briefing at 8:30 a.m. Central European Time (CET) and Dr. Spencer Sullivan, a clinical investigator on the trial, will present the abstract data at 5:30 p.m. (CET).

The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 27643823.  To access a live audio webcast, please visit the “Investors” section at

A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 27643823 or also available on our website.

About Spark Therapeutics

Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. To learn more, please visit

Corporate Contacts:

Stephen W. Webster
Chief Financial Officer
Spark Therapeutics, Inc.Daniel Faga
Chief Business Officer
Spark Therapeutics, Inc.
(855) SPARKTX (1-855-772-7589)

Media Contact:

Ten Bridge CommunicationsDan Quinn
(781) 475-7974

Primary Logo

Spark Therapeutics, Inc.